TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$125 Million

Krystal Biotech

Follow-on Offering

Lead Left Bookrunner, May 2020

Krystal Biotech

Krystal Biotech, Inc. is a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction.  Using its patented platform that is based on engineered herpes simplex virus type 1, or HSV-1, Krystal creates vectors that encode functional proteins. Krystal is primarily focused on applying its platform to treat rare monogenic skin conditions caused by insufficient or completely absent protein production. The Company has expanded its pipeline products to develop medicines to treat chronic, non-monogenic skin diseases and aesthetic skin conditions.  Krystal has also started expanding the scope of its product development beyond dermatology and has begun preclinical efforts in the fields of pulmonary diseases.